Dansk | English
Sitemap
youtube_off.png
linkedin_off.png
Facebook
News

News

Dato
16.03.2017
BONESUPPORT™ Founder Lars Lidgren Receives the 2017 OREF Clinical Research Kappa Delta Award
Lund, Sweden, 16 March, 2017 – BONESUPPORT AB, an emerging leader in innovative injectable bioceramic bone scaffolds to treat bone voids caused by trauma, infection, disease or related surgery, announces that its founder Lars Lidgren, is a member of a  group of Swedish and US Knee and Hip surgeons from Lund and Gothenburg, Sweden, Boston and Rochester U.S. that has received the 2017 OREF Clinical Research Kappa Delta Award. The award was made for the group’s outstanding research contribution leading to improved prosthetic survival and patient outcomes.
Dato
15.03.2017
Vtesse Completes Enrollment of Phase 2b/3 Pivotal Clinical Trial of VTS-270 in Niemann-Pick Type C1 Disease

Company anticipates sharing topline data and completing regulatory submissions in 2018

GAITHERSBURG, Md., March 15, 2017 /PRNewswire/ -- Vtesse, Inc. announced today that its registrational study of investigational drug VTS-270 in Niemann-Pick Type C1 disease (NPC) is fully enrolled. 

Dato
14.03.2017
BONESUPPORTTM EXTENDS U.S. DISTRIBUTION AGREEMENT FOR CERAMENTTM|BONE VOID FILLER
Lund, Sweden, 14 March, 2017 – BONESUPPORT AB, an emerging leader in innovative injectable bioceramic bone scaffolds to treat bone voids caused by trauma, infection, disease or related surgery, announces that it has extended the term of its U.S. distribution agreement with Zimmer Biomet.  Under the agreement, Zimmer Biomet will continue to have exclusive rights for BONESUPPORT’s proprietary CERAMENT BONE VOID FILLER product line for Orthopedics, Trauma and Foot and Ankle indications in the United States.
Dato
10.03.2017
Spero Therapeutics Secures $51.7 Million in Oversubscribed Series C Financing

$51.7 million financing broadens investor base and provides flexibility to advance clinical stage potentiator program and expand antibacterial pipeline

CAMBRIDGE, Mass, March 8, 2017 – Spero Therapeutics, LLC, a biopharmaceutical company founded to develop novel therapies to treat bacterial infections, announced today that it has completed a $51.7 million Series C preferred financing led by new investor GV (formerly Google Ventures). The round includes participation by additional new investors RA Capital Management and Rock Springs Capital as well as existing investors. 

Dato
21.02.2017
First patients entered into Phase II trial of VHsquared's lead Vorabody product V565 HARBOR study of novel anti-TNFα oral domain antibody taking place in North America & Europe

Cambridge, UK, February 20 2017 – VHsquared, the oral domain antibody company, is pleased to announce that the first patients have entered the international Phase II trial of its lead product, V565, in Crohn's disease. The aim of the HARBOR study1 is to show the efficacy of the anti-TNFα oral domain antibody as measured by changes in clinical symptoms, markers of inflammation and endoscopic appearance. It is randomised, doubleblind and placebo-controlled, involving over 100 patients with moderately to severely active Crohn’s disease. VHsquared is developing a portfolio of complementary oral domain antibodies (Vorabodies) which engage validated biological targets with the potential to transform the treatment of inflammatory bowel disease (IBD).

Dato
13.02.2017
ACACIA PHARMA ANNOUNCES POSITIVE RESULTS FROM ITS FOURTH AND FINAL PIVOTAL TRIAL OF BAREMSIS™ FOR THE RESCUE TREATMENT OF PONV

Extensive Phase 3 programme demonstrates clinical potential of BAREMSIS in rescue treatment and prophylaxis of PONV – NDA to be submitted to the US FDA 1H 2017

Cambridge, UK – 13th February 2017: Acacia Pharma Group Ltd (“Acacia Pharma”), the supportive care company developing products for US and international markets, announces positive results from its fourth and final pivotal Phase 3 study investigating BAREMSIS™ (amisulpride injection, formerly APD421) for the rescue treatment of patients who develop post-operative nausea & vomiting (PONV), despite having received prior antiemetic prophylaxis.  

Dato
10.02.2017
ICONIC THERAPEUTICS TO PRESENT PHASE 2a EMERGE TRIAL RESULTS AT MIAMI MEETING
South San Francisco, February 9 – – Iconic Therapeutics, a clinical stage biopharmaceutical company dedicated to translating knowledge of Tissue Factor biology into new therapeutics for retinal disease and cancer, announced today that the results of its recently completed EMERGE trial, a Phase 2a randomized, double-masked, multi-dose study of the drug candidate ICON-1 in wet Age-Related Macular Degeneration (AMD), will be presented for the first time at the Angiogenesis, Exudation, and Degeneration meeting in Miami, FL on Saturday February 11. The trial design included assessment of outcomes specifically designed to measure lesion growth and leakage, both hallmarks of disease progression in AMD. The EMERGE trial was a six-month, active-controlled, multi-center study of 88 patients with newly diagnosed disease. Iconic previously completed an 18-subject Phase 1 clinical trial in neovascular AMD, which demonstrated safety and preliminary evidence of potential biologic activity
Dato
23.01.2017
SANIFIT ANNOUNCES ENROLLMENT OF FIRST PATIENT IN CaLIPSO

a Phase IIb Study for the Treatment of Cardiovascular Calcification in End-Stage-Renal-Disease Patients on Haemodialisis.

San Diego, USA and Palma, Spain, January 23, 2016 - Laboratoris Sanifit S.L., a clinical-stage biopharmaceutical company focused on treatments for calcification disorders, today announced that the first patient has been enrolled in the Phase IIb “CaLIPSO Study” clinical trial of lead candidate, SNF472, for the treatment of cardiovascular calcification (CVC) in end-stage-renal-disease (ESRD) patients on haemodialysis (HD).

Dato
12.01.2017
Vtesse Announces Dosing of First Patient in Australia in Phase 2b/3 Clinical Trial of VTS-270 in Niemann-Pick Type C1 Disease

Clinicians Continuing to Enroll Children with NPC at Trial Sites in the United States, Germany, the United Kingdom, France, Spain, and Turkey 

GAITHERSBURG, Md., Jan. 10, 2017 /PRNewswire/ -- Vtesse, Inc., a company committed to developing medicines to benefit patients with ultra rare, life-threatening diseases, announced today that clinicians have dosed the first trial participants in Australia in the company's global, pivotal clinical trial of investigational drug VTS-270 for Niemann-Pick Type C1 disease (NPC). 

Dato
04.01.2017
scPharmaceuticals Announces Closing of $45.6 Million in Series B Financing

Funding supports preparation for commercial introduction of Furoscix™ and further advancement of the sc2Wear™ drug delivery platform.

LEXINGTON, Mass., Jan. 4, 2017 /PRNewswire/ -- scPharmaceuticals, Inc., a privately held biopharmaceutical company developing transformative pharmaceutical products for subcutaneous delivery announced today that it has closed a $45.6 million Series B investment round. The investment was co-led by OrbiMed and a wholly-owned subsidiary of Sun Pharmaceutical Industries Ltd. (Sun Pharma). In addition to OrbiMed and Sun Pharma, existing investors 5AM Ventures and Lundbeckfond Ventures participated in the financing. This Series B investment will support the development of the operational and commercial infrastructure to bring Furoscix™ and the sc2Wear™ Infusor to market in the United States.

1 2 3 4 5 6 7 8 9 10 Næste 10 Næste